MX2023005338A - Compuestos macrociclicos sustituidos y metodos de tratamiento relacionados. - Google Patents

Compuestos macrociclicos sustituidos y metodos de tratamiento relacionados.

Info

Publication number
MX2023005338A
MX2023005338A MX2023005338A MX2023005338A MX2023005338A MX 2023005338 A MX2023005338 A MX 2023005338A MX 2023005338 A MX2023005338 A MX 2023005338A MX 2023005338 A MX2023005338 A MX 2023005338A MX 2023005338 A MX2023005338 A MX 2023005338A
Authority
MX
Mexico
Prior art keywords
treatment
related methods
macrocyclic compounds
substituted macrocyclic
substituted
Prior art date
Application number
MX2023005338A
Other languages
English (en)
Inventor
Hoan Huynh
Srinivasa Karra
Younggi Choi
Yuan Hu
Daljit Matharu
Lewis D Pennington
Brian M Aquila
Ingo Andreas Mugge
James R Woods
Brian Kenneth Raymer
Jörg Martin Bentzien
Jonathan Ward Lehmann
Michael R Hale
Roman A Valiulin
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of MX2023005338A publication Critical patent/MX2023005338A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona compuestos útiles para el tratamiento de la narcolepsia o cataplejía en un sujeto que lo necesita. También se proporcionan en la presente descripción composiciones farmacéuticas y métodos relacionados.
MX2023005338A 2020-12-21 2021-12-21 Compuestos macrociclicos sustituidos y metodos de tratamiento relacionados. MX2023005338A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063128404P 2020-12-21 2020-12-21
US202163190937P 2021-05-20 2021-05-20
PCT/US2021/064483 WO2022140316A1 (en) 2020-12-21 2021-12-21 Substituted macrocyclic compounds and related methods of treatment

Publications (1)

Publication Number Publication Date
MX2023005338A true MX2023005338A (es) 2023-05-22

Family

ID=80050560

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005338A MX2023005338A (es) 2020-12-21 2021-12-21 Compuestos macrociclicos sustituidos y metodos de tratamiento relacionados.

Country Status (9)

Country Link
US (1) US12006330B2 (es)
EP (1) EP4263555A1 (es)
JP (1) JP2024501641A (es)
KR (1) KR20230127254A (es)
AU (1) AU2021409403A1 (es)
CA (1) CA3172841A1 (es)
IL (1) IL303848A (es)
MX (1) MX2023005338A (es)
WO (1) WO2022140316A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022009938A2 (pt) 2019-11-25 2022-09-13 Alkermes Inc Compostos macrocíclicos substituídos e métodos de tratamento relacionados
US20240002397A1 (en) * 2020-11-23 2024-01-04 Merck Sharp & Dohme Llc 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists
WO2022232025A1 (en) * 2021-04-26 2022-11-03 Alkermes, Inc. Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
CA3219490A1 (en) * 2021-05-26 2022-12-01 Alkermes, Inc. Substituted carbamate macrocyclic compounds and related methods of treatment
CA3219506A1 (en) * 2021-05-26 2022-12-01 Hoan Huynh Substituted fused bicyclic macrocyclic compounds and related methods of treatment
WO2024112899A1 (en) * 2022-11-23 2024-05-30 Vertex Pharmaceuticals Incorporated Substituted macrocyclic amine modulators of orexin receptor 2
WO2024160822A1 (en) * 2023-01-31 2024-08-08 Jazz Pharmaceuticals Ireland Limited Macrocyclic orexin receptor agonists and uses thereof
WO2024189597A1 (en) * 2023-03-16 2024-09-19 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
US9527807B2 (en) 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
CA2867494C (en) 2012-03-17 2020-03-24 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2015048091A1 (en) 2013-09-24 2015-04-02 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
EP3068783B1 (en) 2013-11-15 2020-09-23 The Board of Trustees of the Leland Stanford Junior University Agonists of hypocretin receptor 2 for use for treating heart failure
PE20161064A1 (es) 2013-12-12 2016-10-28 Univ Tsukuba Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo
WO2015147240A1 (ja) 2014-03-28 2015-10-01 国立大学法人筑波大学 敗血症の予防治療剤
MX2017003254A (es) 2014-09-11 2017-10-12 Janssen Pharmaceutica Nv 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
JP6746107B2 (ja) 2015-02-19 2020-08-26 国立大学法人 筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2016199906A1 (ja) 2015-06-12 2016-12-15 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
RS62861B1 (sr) 2016-02-04 2022-02-28 Takeda Pharmaceuticals Co Supstituisano piperidin jedinjenje i njegova upotreba
EP3594202B1 (en) 2017-03-08 2021-08-11 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
WO2018164191A1 (ja) 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
SG11202000831XA (en) 2017-08-03 2020-02-27 Takeda Pharmaceuticals Co Heterocyclic compound and use thereof
US11319286B2 (en) 2017-08-03 2022-05-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
US11324724B2 (en) 2017-09-28 2022-05-10 Boehringer Ingelheim International Gmbh N-(2,2-difluoroethyl)-N-[(pyrimidinylamino)propanyl]arylcarboxamides
US11673867B2 (en) 2017-12-12 2023-06-13 University Of Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid-addition salt
SG11202009615UA (en) 2018-03-27 2020-10-29 Univ Texas Ox2r compounds
US12077522B2 (en) 2018-06-29 2024-09-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
US11655241B2 (en) 2018-06-29 2023-05-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP7379374B2 (ja) 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
JP7408569B2 (ja) 2018-12-12 2024-01-05 武田薬品工業株式会社 複素環化合物
AU2020215380A1 (en) 2019-01-31 2021-08-19 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP3923933A4 (en) 2019-02-13 2022-08-17 Merck Sharp & Dohme Corp. PYRROLIDINE-LIKE OREXIN RECEPTOR AGONISTS
TW202045476A (zh) 2019-02-13 2020-12-16 美商默沙東藥廠 5-烷基吡咯啶食慾素受體促效劑
US20230018413A1 (en) 2019-08-08 2023-01-19 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
BR112022004576A2 (pt) 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica
BR112022009938A2 (pt) 2019-11-25 2022-09-13 Alkermes Inc Compostos macrocíclicos substituídos e métodos de tratamento relacionados
US11352357B2 (en) 2019-11-27 2022-06-07 Sumitomo Dainippon Pharma Co., Ltd. Cycloalkylurea derivative
BR112022010323A2 (pt) 2019-11-27 2022-08-16 Takeda Pharmaceuticals Co Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal
AU2021205892A1 (en) 2020-01-10 2022-08-18 Takeda Pharmaceutical Company Limited A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450
AU2021308053A1 (en) 2020-07-17 2023-02-02 Eisai R&D Management Co., Ltd. Substituted piperidine compound and application thereof
US20230257348A1 (en) 2020-08-18 2023-08-17 Merck Sharp & Dohme Llc Cyclopentapyrrole orexin receptor agonists
KR20230053639A (ko) 2020-08-18 2023-04-21 머크 샤프 앤드 돔 엘엘씨 비시클로헵탄 피롤리딘 오렉신 수용체 효능제
TW202227397A (zh) 2020-09-03 2022-07-16 英商歐瑞夏治療公司 雙環的－雜環衍生物及相關用途
TW202227433A (zh) 2020-09-03 2022-07-16 英商歐瑞夏治療公司 中環或大環之經苄基取代的雜環衍生物及相關用途
JP2022064180A (ja) 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物
MX2023005073A (es) 2020-11-02 2023-05-16 Merck Sharp & Dohme Llc Agonistas macrociclicos de los receptores de urea orexina.
US20240002397A1 (en) 2020-11-23 2024-01-04 Merck Sharp & Dohme Llc 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists
US20240002359A1 (en) 2020-12-03 2024-01-04 Merck Sharp & Dohme Llc 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists
EP4262788A4 (en) 2020-12-16 2024-10-30 Merck Sharp & Dohme Llc UREA-OREXIN RECEPTOR AGONISTS
US20240174605A1 (en) 2021-03-03 2024-05-30 Research Triangle Institute Arylsulfonamides as orexin receptor agonists
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
TW202309051A (zh) 2021-05-03 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 食慾素受體促效劑及其用途
IL308659A (en) 2021-05-26 2024-01-01 Sumitomo Pharma Co Ltd The history of phenylurea
US20240360081A1 (en) 2021-06-25 2024-10-31 Jazz Pharmaceuticals Ireland Limited Sulfonamide orexin receptor agonists and uses thereof
TW202321272A (zh) 2021-08-13 2023-06-01 英商歐瑞夏治療公司 肽衍生物和作為食慾激素促效劑之相關用途

Also Published As

Publication number Publication date
EP4263555A1 (en) 2023-10-25
US12006330B2 (en) 2024-06-11
US20220194958A1 (en) 2022-06-23
IL303848A (en) 2023-08-01
WO2022140316A1 (en) 2022-06-30
AU2021409403A1 (en) 2023-05-25
JP2024501641A (ja) 2024-01-15
KR20230127254A (ko) 2023-08-31
CA3172841A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
MX2022006206A (es) Compuestos macrociclicos sustituidos y metodos de tratamiento relacionados.
MX2023005338A (es) Compuestos macrociclicos sustituidos y metodos de tratamiento relacionados.
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021012638A (es) Compuestos biciclicos.
MX2020012731A (es) Inhibidores de kras g12c y metodos para su uso.
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
MX2021005314A (es) Compuestos biciclicos.
CY1125659T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
EA201992781A1 (ru) Ингибиторы g12c kras и способы их применения
MX2021012216A (es) Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
MY201925A (en) Macrocyclic compounds and uses thereof
CR20240144A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
MX2020007974A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
MX2022014007A (es) Compuestos como inhibidores de bcl-2.
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
MX2023013173A (es) Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos.
MX2024004993A (es) Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos.
CR20210614A (es) Nuevos inhibidores de egfr
MX2023008634A (es) Análogos de rapamicina y usos de estos.
MX2022013964A (es) Inhibidores de glucosilceramidasa no lisosomal y los usos de los mismos.